Company intelligence / Profile preview

Carmot Australia First Pty Ltd

Docklands, Victoria, Australia

Ownership: Private
Employees: ~70
Development stage: Other

Overview

Carmot's lead asset (CT-388) demonstrated substantial weight loss in Phase 1b studies and is being developed as a dual GLP-1/GIP receptor agonist for obesity and diabetes. Additional assets (CT-996, CT-868) are in Phase 1 and Phase 2 trials, respectively, for obesity, type 2 and type 1 diabetes. All assets have shown encouraging early clinical safety and efficacy results, with CT-388 displaying best-in-class potential for weight loss and metabolic diseases[2][1][4].

Therapeutic areas: Endocrinology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Roche

Beyond the preview

Go deeper on Carmot Australia First Pty Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carmot Australia First Pty Ltd.

Explore the full profile